Journal Mobile Options
Table of Contents
Vol. 84, No. 3, 2010
Issue release date: April 2010
Urol Int 2010;84:292–300

Renal Cell Carcinoma in Young Adults: A Study of 130 Cases and a Review of Previous Series

López J.I. · Moreno V. · García H. · Antón I. · Robles A. · Oñate J.M. · Baños Á. · Escandón J. · Ugalde A.
Departments of Pathology,aHospital de Cruces, Basque Country University (EHU/UPV), Barakaldo, bHospital de Txagorritxu, Basque Country University (EHU/UPV), Vitoria-Gasteiz, cHospital 12 de Octubre, Complutense University, Madrid, dPOVISA, Vigo, eHospital de Valme, University of Sevilla, Sevilla, fHospital del Rio Hortega, University of Valladolid, Valladolid, gHospital General Yagüe, Burgos, hHospital Peset, University of Valencia, Valencia, and iHospital de Basurto, Basque Country University (EHU/UPV), Bilbao, Spain

Individual Users: Register with Karger Login Information

Please create your User ID & Password

Contact Information

I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in


Objective: To characterize a large series of renal cell carcinomas (RCCs) in young patients and to compare the data obtained to previously published data. Patients and Methods: A total of 130 RCCs diagnosed in patients <40 years of age were collected from 9 different hospitals in Spain. Cases were re-evaluated following the diagnostic criteria of the 2004 WHO classification of renal tumors. Results: Histologically, tumors were classified as clear cell (50.7%), papillary (8.5%), chromophobe (14.6%), unclassified (16.9%) and clear cell papillary (9.3%) RCCs. Organ-confined disease (OCD) was detected in 83.6% of the cases. Tumor size and Fuhrman’s grade were statistically correlated (Spearman’s ρ = 0.391). CD10 (p = 0.000), CK7 (p = 0.000), CD15 (p = 0.016), CD117 (p = 0.000), 34βE12 cytokeratin (p = 0.034) and e-cadherin (p = 0.000) immunostaining significantly differentiated the five histological categories. Conclusions: OCD was more common in young RCC patients. The clear cell phenotype accounted for only 50% of RCCs in this age group, with an increasing number of chromophobe and unclassified RCCs. Clear cell RCCs with a papillary growth pattern accounted for a significant proportion of the cases.

Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.


  1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ: Cancer statistics, 2007. CA Cancer J Clin 2007;57:43–66.
  2. Lopez-Beltran A, Scarpelli M, Montironi R, Kirkali Z: 2004 WHO classification of the renal tumors of the adults. Eur Urol 2006;49:798–805.
  3. Murphy WM, Grignon DJ, Perlman EJ: AFIP Atlas of Tumor Pathology, Series 4. Tumors of the Kidney, Bladder, and Related Urinary Structures. Washington, American Registry of Pathology, 2004, pp 101–109.
  4. Lieber MM, Tomera FM, Taylor WF, Farrow GM: Renal adenocarcinoma in young adults: survival and variables affecting prognosis. J Urol 1981;125:164–168.
  5. Schiff M Jr, Herter G, Lytton B: Renal adenocarcinoma in young adults. Urology 1985;25:357–359.
  6. Rainwater LM, Zincke H, Farrow GM, Gonchoroff NJ: Renal cell carcinoma in young and old patients. Urology 1991;38:1–5.
  7. Boykin WH, Bright KE, Zeidman EJ, Thompson IM: Renal tumors in young adults. Urology 1992;40:503–505.
  8. Fernández Gómez JM, Rábade Rey CJ, Pérez García FJ, Sahagun-Angüello JL, Martínez Gómez FJ, Alonso-Sáinz F: Renal adenocarcinoma in young patients (in Spanish). Actas Urol Esp 1997;21:22–27.

    External Resources

  9. Asanuma H, Nakai H, Takeda M, et al: Renal cell carcinoma in children: experience at a single institution in Japan. J Urol 1999;162:1402–1405.
  10. Yusim I, Mermershtain W, Neulander E, Eidelberg I, Gusakova I, Kaneti J: Influence of age on the prognosis of patients with renal cell carcinoma (RCC). Onkologie 2002;25:548–550.
  11. Maoudouni S, En-Nia I, Rioux-Leclerq N, et al: Renal cell carcinoma before the age of 40: prognostic factors. Prog Urol 2002;12:575–578.

    External Resources

  12. Rodriguez A, Tazi H, Patard JJ, Lobel B: Le cancer du rein de l’adulte de moins de 40 ans: un cancer particulier? Incidence, évolution et revue de la littérature. Ann Urol (Paris) 2003;37:155–159.
  13. Sánchez-Ortiz RF, Rosser CJ, Madsen LT, Swanson DA, Wood CG: Young age is an independent prognostic factor for survival of sporadic renal cell carcinoma. J Urol 2004;171:2160–2165.
  14. Abou El Fettouh HI, Cherullo EE, El-Jack M, Al Maslamani YA, Novick AC: Sporadic renal cell carcinoma in young adults: presentation, treatment, and outcome. Urology 2002;60:806–810.
  15. Eggener SE, Rubenstein JR, Smith ND, et al: Renal tumors in young adults. J Urol 2004;171:106–110.
  16. Goetzl MA, Desai M, Mansukhani M, et al: Natural history and clinical outcome of sporadic renal cortical tumors diagnosed in the young adult. Urology 2004;63:41–45.
  17. Gillett MD, Cheville JC, Karnes J, et al: Comparison of presentation and outcome for patients 18 to 40 and 60 to 70 years old with solid renal masses. J Urol 2005;173:1893–1896.
  18. Taccoen X, Valeri A, Descotes JL, et al: Renal cell carcinoma in adults 40 years old or less: young age is an independent prognostic factor for cancer-specific survival. Eur Urol 2007;51:980–987.
  19. Zugor V, Fridel S, Lausen B, Schott GE, Kühn R, Labanaris AP: Renal cell carcinoma under 35 years of age: comparison of survival rates for symptomatic and asymptomatic patients. Int Urol Nephrol 2008;40:289–293.
  20. Argani P, Ladanyi M: Translocation carcinomas of the kidney. Clin Lab Med 2005;25:363–378.
  21. Gobbo S, Eble JN, Grignon DJ, et al: Clear cell papillary renal cell carcinoma: a distinct histopathologic and molecular genetic entity. Am J Surg Pathol 2008;32:1239–1245.
  22. Gobbo S, Eble JN, MacLennan GT, et al: Renal cell carcinomas with papillary architecture and clear cell components: the utility of immunohistochemistry and cytogenetical analyses in differential diagnosis. Am J Surg Pathol 2008;32:1780–1786.
  23. Fuhrman SA, Lasky LC, Limas C: Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol 1982;6:655–663.
  24. Greene FL, Page DL, Fleming ID, et al (eds): AJCC Cancer Staging Manual, ed 6. New York, Springer, 2002.
  25. Jonasch E, Tannir NM: Adjuvant and neoadjuvant therapy in renal cell carcinoma. Cancer J 2008;14:315–319.
  26. Amin MB, Paner GP, Alvarado-Cabrero I, et al: Chromophobe renal cell carcinoma: histomorphologic characteristics and evaluation of conventional pathologic prognostic parameters in 145 cases. Am J Surg Pathol 2008;32:1822–1834.
  27. Fuzesi L, Gunawan B, Bergmann F, Tack S, Braun S, Jakse G: Papillary renal cell carcinoma with clear cell cytomorphology and chromosomal loss of 3p. Histopathology 1999;35:157–161.
  28. Salama ME, Worsham MJ, de Peralta-Venturina M: Malignant papillary renal tumors with extensive clear cell change. A molecular analysis by microsatellite analysis and fluorescence in situ hybridization. Arch Pathol Lab Med 2003;127:1176–1181.
  29. Tickoo SK, de Peralta-Venturina MN, Harik LR, Worcester HD, Salama ME, Young AN, Moch H, Amin MB: Spectrum of epithelial neoplasms in end-stage renal disease. An experience from 66 tumor-bearing kidneys with emphasis on histologic patterns distinct from those in sporadic adult renal neoplasia. Am J Surg Pathol 2006;30:141–153.
  30. Rohan SM, Dudas ME, Gopalan A, Fine SW, Reuter VE, Tickoo SK: Clear cell papillary renal cell carcinoma: a distinct entity or a variant of clear cell renal cell carcinoma? Mod Pathol 2009;22:191A.

    External Resources

  31. Aydin H, Sercia L, Magi-Galluzzi C, Zhou M: Expanding the morphological spectrum of clear cell papillary renal cell carcinoma, a distinct renal cell carcinoma subtype. Mod Pathol 2009;22:158A.

    External Resources

  32. Zhou M, Roma A, Magi-Galluzzi C: The usefulness of immunohistochemical markers in the differential diagnosis of renal neoplasms. Clin Lab Med 2005;25:247–257.

Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50